Cipher Pharmaceuticals Reports Record Q2 2025 Revenue

Cipher Pharmaceuticals Inc ( (CPHRF) ) has released its Q2 earnings. Here is a breakdown of the information Cipher Pharmaceuticals Inc presented to its investors.

Cipher Pharmaceuticals Inc., a specialty pharmaceutical company focused on dermatology, has reported its financial results for the second quarter of 2025, showcasing significant growth and record revenue. The company, known for acquiring and marketing products that address unmet medical needs, operates primarily in Canada, the U.S., and South America.

In the second quarter of 2025, Cipher Pharmaceuticals achieved its highest single-quarter revenue in history, amounting to $13.4 million, marking a 152% increase compared to the same period last year. The company’s adjusted EBITDA also saw a substantial rise of 148%, reaching $7.6 million. A key contributor to this growth was the performance of Natroba™, which generated $7.8 million in sales, reflecting a 16% sequential increase from the previous quarter.

The company’s Canadian product portfolio also experienced growth, with revenue increasing by 12% to $4.1 million. Additionally, Cipher demonstrated strong cash generation, with $6.0 million from operations, and made significant debt repayments totaling $15.0 million during the quarter, further strengthening its financial position.

Looking ahead, Cipher Pharmaceuticals remains focused on expanding its market share for Natroba™ in the U.S. and obtaining regulatory approval in Canada. The company aims to enhance its North American platform by acquiring complementary dermatology products, thereby driving profitability and shareholder value.